2018 Annual Meeting of the American Association for the Study of Liver Diseases*

November 9-13, 2018; San Francisco, California
Download slides or audio, review Capsule Summaries, and read ClinicalThought commentaries on practice-changing viral hepatitis and NAFLD/NASH data from San Francisco.

Viral Hepatitis

Capsule Summaries

Baseline characteristics including demographic factors and those related to drug use were not associated with decreased rates of SVR12.

Released: November 15, 2018

Addition of ribavirin to glecaprevir/pibrentasvir associated with anemia and no improvement in efficacy.

Released: November 20, 2018

Among patients who received 12 weeks of SOF/VEL/VOX, lower SVR rates observed in those with genotype 1-3 HCV infection previously treated with SOF/VEL.

Released: November 14, 2018

TDF was associated with a significantly lower risk of cirrhosis but no significant difference in liver inflammatory score improvement vs placebo.

Released: November 20, 2018

In this open-label phase IIIb trial, no patients with genotype 1, 2, 4, 5, or 6 HCV infection and compensated cirrhosis experienced virologic failure with 8 weeks of GLE/PIB; enrollment of patients with genotype 3 HCV infection and compensated cirrhosis is ongoing.

Released: November 21, 2018

Use of DAA therapy also had no impact on patterns of HCC recurrence in this retrospective multicenter study.

Released: November 12, 2018
Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Educational grant provided by:
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?